Dexamethasone in critical coronavirus disease-2019 cases: Insights from a cross-sectional study

Abstract

Objective: The objective of the study is to describe the clinical and laboratory characteristics of critically ill coronavirus disease-2019 (COVID-19) patients treated with dexamethasone in an intensive care unit (ICU) to provide a support tool for clinical decision-making. Design: A survey was conducted among hospitalized patients from November 2020 to March 2021, with data collected through patient interviews, medical records, and laboratory tests. Setting: This is a large hospital serving as a reference center for COVID-19 care in Bahia, Brazil. Patients: A convenience sample of 22 patients admitted to the COVID-19 ICU who signed informed consent to participate in the study. Methods: A cross-sectional study of patients admitted to the ICU with COVID-19. Data were analyzed using statistical methods. Results: The most common comorbidities among patients were hypertension (54%), diabetes (36%), and cardiovascular disease (27%). Among the deaths recorded, 55% of patients had hypertension, 44% had diabetes and/or required insulin therapy, 33% had a history of cardiovascular disease (including atrial fibrillation and congestive heart failure), and 22% had a history of stroke. Renal dysfunction (elevated creatinine); liver function abnormalities (increased alanine aminotransferase and aspartate aminotransferase); and elevated levels of ferritin, fibrinogen, and D-dimer were identified as potential indicators of disease progression. Among these factors, only elevated creatinine demonstrated a statistically significant association with an increased mortality risk. Conclusion: These findings provide a better understanding of the clinical course of severe acute respiratory syndrome coronavirus 2 infections and suggest that laboratory medicine is crucial in supporting clinical decision-making and advancing scientific and healthcare knowledge during the early phases of the COVID-19 pandemic. Relevance for patients: Identifying key risk factors, such as renal dysfunction, can improve early intervention and personalized treatment for critically ill COVID-19 patients.

Keywords

Intensive care unit / SARS-COV-2 / Hospitalized patients / Clinical and laboratory features

Funding

The work was supported by the Capes Finance Code 001.

Conflict of interest

All authors report no conflicts of interest relevant to this article.

References

[1] World Health Organization. Coronavirus Disease (COVID-19) Outbreak Situation>. Geneva, Switzerland: World Health Organization; 2020.

[2] Huang JF, Wang XB, Zheng KI, et al.Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19. Metabolism. 2020;108:154249. doi: 10.1016/j.metabol.2020.154249

[3] Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020; 58(7):1131-1134. doi: 10.1515/cclm-2020-0198

[4] Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Clin Chim Acta. 2020; 510:475-482. doi: 10.1016/j.cca.2020.08.019

[5] Bataille S, Pedinielli N, Bergounioux JP. Could ferritin help the screening for COVID-19 in hemodialysis patients? Kidney Int. 2020; 98(1):235-236. doi: 10.1016/j.kint.2020.04.017

[6] Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020; 19(6):102538. doi: 10.1016/j.autrev.2020.102538

[7] Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. doi: 10.1056/nejmoa2002032

[8] Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63(3):364-374. doi: 10.1007/s11427-020-1643-8

[9] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis. Int J Infect Dis. 2016; 49:129-133. doi: 10.1016/j.ijid.2016.06.015

[10] Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017; 198(10):4046-4053. doi: 10.4049/jimmunol.1601896

[11] Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients With COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020; 180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539. Erratum in: JAMA Intern Med. 2021;181(7):1021. doi: 10.1001/jamainternmed.2021.1229

[12] Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract. 2020; 14(4):295-300. doi: 10.1016/j.orcp.2020.07.002. Retraction in: Obes Res Clin Pract. 2021;15(1):100. doi: 10.1016/j.orcp.2020.12.008

[13] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Erratum in: Lancet. 2020;395(10223):496. doi: 10.1016/S0140-6736(20)30252-X

[14] Sharifipour E, Shams S, Esmkhani M, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis. 2020;20:646. doi: 10.1186/s12879-020-05374-z

[15] Chan L, Chaudhary K, Saha A, et al.AKI in Hospitalized Patients with COVID-19. J Am Soc Nephrol. 2021; 32(1): 151-160. doi: 10.1681/ASN.2020050615

[16] Ng JH, Hirsch JS, Hazzan A, et al. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis. 2021; 77(2):204-215.e1. doi: 10.1053/j.ajkd.2020.09.002

[17] Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 2005; 67(2):698-705. doi: 10.1111/j.1523-1755.2005.67130.x

[18] Yang X, Tian S, Guo H. Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis. Int Immunopharmacol. 2021;90:107159. doi: 10.1016/j.intimp.2020.107159

[19] RECOVERY Collaborative Group, Horby P, Lim WS, et al.Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693-704. doi: 10.1056/NEJMoa2021436